


Listing of the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1 and 24 as follows:

1. (currently amended) A compound in accord with structural diagram I:



I

wherein:

R^1 at each occurrence is independently selected from CN, CF_3 , OCF_3 , $OCHF_2$, halogen, ~~$C_{2-4}alkenyl$, $C_{2-4}alkynyl$~~ , hydrogen, $C_{1-6}alkyl$, $C(O)R^c$, $C(O)NHR^c$, CO_2R^c , NR^aR^b , $CH_2NR^aR^b$, OR^a and CH_2OR^a , wherein R^a and R^b are independently at each occurrence hydrogen, $C_{1-6}alkyl$, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c ; and wherein where R^c at each occurrence is $C_{1-6}alkyl$; ~~or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$;~~

m is 1, 2 or 3, where at least one R^1 moiety is other than hydrogen;

R^2 and R^3 are independently hydrogen, $C_{1-6}alkyl$ or $C_{1-6}alkyl$ substituted with $C_{1-4}alkoxy$;

R^4 at each occurrence is independently selected from hydrogen, CF_3 , OCF_3 , $OCHF_2$, halogen, $C_{1-4}alkyl$, NR^aR^b , $CH_2NR^aR^b$, OR^a and CH_2OR^a , wherein R^a and R^b are independently at each occurrence hydrogen, $C_{1-6}alkyl$, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c ; and wherein R^c at each occurrence is $C_{1-6}alkyl$; ~~or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$;~~

n is 0, 1, 2 or 3;

G is oxygen;

j is 1, 2, 3 or 4;

~~k is 1 or 2;~~

or a pharmaceutically-acceptable salt thereof.

2. (previously presented) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, C_{1-6} alkyl or OR^c ; and m is 1, 2 or 3;

R^2 and R^3 are independently hydrogen or C_{1-6} alkyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

or a pharmaceutically-acceptable salt thereof.

3. (previously presented) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;


R^2 and R^3 are independently hydrogen or methyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

R^4 independently at each occurrence is halogen where n is 1 or 2;

or a pharmaceutically-acceptable salt thereof.

4. (previously presented) A compound according to Claim 1, according to structural diagram II



II

wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl,

3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-difluoromethoxyphenyl and 4-trifluoromethoxyphenyl;

R^1 is selected from H, methyl, ethyl and methoxy where m is 1 or 2, and

R^2 and R^3 are independently selected from H and methyl, and

or a pharmaceutically-acceptable salt thereof.

5. (canceled).

6. (previously presented) The pharmaceutically-acceptable salt according to Claim 1, wherein said salt is formed from an inorganic or organic acid selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic and quinic acids.

7. (previously presented) A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

8-9. (canceled).

10. (previously presented) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, in a mammal, comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

11-15. (canceled).

16. (previously presented) A method for treating depression, comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

17. (previously presented) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

18. (previously presented) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

19. (previously presented) A method for treating depression, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

20. (previously presented) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.

21. (previously presented) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an

effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

22. (previously presented) A method for treating depression, comprising administering an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

23. (previously presented) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.

24. (currently amended) A compound according to Claim 1, wherein said compound is selected from:

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3 -cyano-2-methoxynaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3 ,4-dichlorophenyl)-4-(3-(3 -cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(4-~Chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-y-l))piperidine;

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-(2-Methoxyethyl)-4-(4-chlorophenyl)-4-(3-(3 -cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-aza-prop-1-yl)piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2,4-dimethoxy-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-difluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-N-methyl-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azapro-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-

yl)piperidine;

~~1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;~~

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-methoxy-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-chloro-3-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

3-cyano-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2,4-dimethoxy-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2,4-dimethoxy-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;

and

3-cyano-N-methyl-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide; or
pharmaceutically acceptable salt thereof.

25. (previously presented) A compound selected from:

3-cyano-N-((4-(3,4-methylenedioxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-2-methoxy-1-naphthamide;

N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-2-ethyl-1-naphthamide; and

N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-N-methyl-1-naphthamide;

or pharmaceutically acceptable salt thereof.

26. (previously presented) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an effective amount of a compound according to Claim 25, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

27. (previously presented) A method for treating depression, comprising administering an effective amount of a compound according to Claim 25, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.

28. (previously presented) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 25, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.